


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL:

USAN	REGADENOSON
PRONUNCIATION	re ga den' oh son
THERAPEUTIC CLAIM	Intravenous use in radionuclide myocardial perfusion imaging as a pharmacologic stress agent to produce coronary vasodilation

CHEMICAL NAMES

1. Adenosine, 2-[4-[(methylamino)carbonyl]-1*H*-pyrazol-1-yl]-, monohydrate
2. 1-(6-amino-9-β-D-ribofuranosyl-9*H*-purin-2-yl)-*N*-methyl-1*H*-pyrazole-4-carboxamide, monohydrate

STRUCTURAL FORMULA



MOLECULAR FORMULA	$\text{C}_{15}\text{H}_{18}\text{N}_8\text{O}_5 \cdot \text{H}_2\text{O}$
MOLECULAR WEIGHT	408.4
TRADEMARK	None assigned
MANUFACTURER	CV Therapeutics, Inc.
CODE DESIGNATION	CVT-3146
<u>CAS</u> REGISTRY NUMBER	875148-45-1